May 18, 2022
Life Sciences
  • The Food and Drug Administration (FDA) authorized a booster dose of the Pfizer-BioNTech COVID-19 vaccine for children between the ages of 5 and 11. The booster can be administered five months after completion of the primary vaccine series. Data released by Pfizer last month found a 36-fold increase in the level of neutralizing antibodies against the omicron variant, compared to two doses. The FDA still has not authorized a vaccine for children under 5, but the agency’s advisory committee is scheduled to consider the matter next month. (Press release here; Articles here, here, here, here, and here)